Valeant gets right to develop AstraZeneca's psoriasis drug
September 01, 2015 at 02:31 AM EDT
(Reuters) - Canada's Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.